New Jersey Bioscience Center Newsletter

SECOND QUARTER 2023

<u>Life Sciences Ecosystem</u> <u>News in New Jersey</u>

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of \$350 Million of American Depositary Shares | Business Wire (Somerset)

Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock | Phathom Pharmaceuticals, Inc. (Florham Park) - The gross proceeds are expected to be ~\$130M.

Celularity Announces \$45 Million Purchase Order, First Middle East Private Label Agreement for Celularity's Halal-certified Biomaterial Products – Celularity (Florham Park)

<u>Citius Pharmaceuticals Announces Closing</u> of \$15 Million Registered Direct Offering (prnewswire.com) (Cranford)

Evergreen Theragnostics Completes \$15M Series B, Launches Discovery Unit, and Prepares Ga-68 DOTATOC Supply Chain (prnewswire.com) (Springfield)

Soligenix Announces Pricing of \$8.5 Million Public Offering (yahoo.com) (Princeton)

New Jersey Bioscience Center In The News

LinusBIO Moves To Incubator at North Brunswick / Announces \$8M Raise

The New Jersey Economic Development Authority (NJEDA) is pleased to welcome LinusBio as a new resident at the Incubator at North Brunswick. LinusBio, a Mt. Sinai spinoff, is a leader in precision exposome sequencing. On May 31st, <u>LinusBio announced an \$8 million A2 round</u> to deliver a novel platform that bridges genomics, the environment, and biological response. This brings the total funding raised by LinusBio to over \$25 million in the last 18 months. Linus also recently announced a <u>collaboration with Novozymes</u> to test a new, non-invasive technology in a clinical trial.

Hopkins MedTech Moves To Incubator at North Brunswick / Awarded Top IVD Provider

Hopkins MedTech, another new resident at the Incubator at North Brunswick, was recently named a Top 10 Emerging in vitro diagnostic (IVD) solutions company by "MedTech Outlook." Hopkins' research and development (R&D) services arm will create a CLIA approved diagnostic testing center at the New Jersey Bioscience Center (NJBC).

BioAegis Therapeutics Announces Two Studies

In April, <u>BioAegis Therapeutics Inc.</u>, a clinical-stage company developing therapies for infectious, inflammatory, and degenerative diseases, announced the publication of two new research studies exploring gelsolin's role in type 2 diabetes. BioAegis is a current resident of the Step-Out Labs and a graduate of the Incubator at North Brunswick.

Meridian Bioscience Announces FDA Clearance

Step-Out Labs resident <u>Meridian Bioscience</u> announced in April that the US Food and Drug Administration (FDA) had granted clearance for the company's new Curian[®] Shiga Toxin assay. This assay expands Meridian's Curian diagnostic platform for the gastrointestinal disease testing market.

Doehler Grand Opening at NJBC

Doehler North America announced its new office and lab hub on April 26th. The newly inaugurated facility, located at NJBC, is a state-of-the-art center with a focus on flavor and taste modulation innovation. The site will also act as an East Coast Hub for <u>Doehler Ventures</u> which supports early-stage startups.

Incubator Labs at the New Jersey Bioscience Center Research Park

The <u>Incubator at North Brunswick</u> will have small labs available in the future. <u>Email</u> or call NJ Bioscience Center Director Lenzie Harcum (732-839-1880) with any questions or to request a tour of the Incubator at North Brunswick.

New Jersey Bioscience Center Alumni In The News

PDS Biotech Receives NOL Benefits from NJ

"We are pleased to receive funds from the <u>New Jersey NOL program</u>," said PDS Biotech Chief Financial Officer Matthew Hill. In May, the company <u>completed enrollment in the immune</u> checkpoint inhibitor naïve group of its VER-SATILE-002 phase II study on pipeline candidate PDS0101. PDS Biotech is a graduate of the Incubator at North Brunswick.





NEW JERSEY BIOSCIENCE CENTER

675 US-1, North Brunswick

Township, NJ 08902

Visikol Founders Appointed to 2023 Health Care Power 50 by NJBIZ

Under the leadership of co-founders Michael Johnson and Tom Villani, who were both named to NJBIZ's 2023 Health Care Power 50, Visikol's rapid growth has continued since it launched in 2016 at Rutgers University. Visikol has many of the top 20 pharmaceutical companies among its clients and has helped in the discovery and development of dozens of drug companies. In 2021, it was acquired by CELLINK. Visikol is a graduate of the Incubator at North Brunswick.

Bellerophon Therapeutics Announces \$5 Million Registered Direct Offering

In March, **Bellerophon Therapeutics** Announced a \$5 million Registered Direct Offering. In May, the <u>Incubator at</u> <u>North Brunswick graduate</u> reported first-quarter net income of \$2.8 million after reporting a loss in the same period a year earlier.

New Jersey Bioscience Center Newsletter

SECOND QUARTER 2023

Life Sciences Ecosystem News in New Jersey

Diligent Pharma, Inc. Announces Completion of \$8.27 Million Series A Financing Raised | Business Wire (Princeton)

Agile Therapeutics Announces Pricing of \$7.5 Million Public (globenewswire.com) (Princeton)

OncoSec Announces \$1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (prnewswire.com) (Ewing)

Onyx Equities Announces New Jersey's Newest Life Sciences and Biotechnology Hub (prnewswire.com) (Kenilworth)

<u>CBRE arranges long-term lease for phar-</u> maceutical company to relocate to Morris <u>County | ROI-NJ</u> CBRE inked a 27,500square-foot lease transaction for Generichem to relocate to Morris County

<u>Plans Announced for Phase II of HELIX</u> <u>in New Brunswick</u>

Funding, Grants and Incentives for Life Science Companies

NJEDA Opens 2023 Net Operating Loss Program Application

The NJEDA opened applications for its 2023 Net Operating Loss (NOL) Program last month. The program enables early stage life sciences and technology businesses that have yet to reach profitability to sell a percentage of their New Jersey net operating losses and unused R&D tax credits to unrelated profitable corporations for cash. The NOL Program is accepting applications through June 30, 2023 at http://www.njeda.com/nol

NJ Innovation Evergreen Fund - NJEDA Board Approves Inaugural Group of Qualified Venture Firms for the New Jersey Innovation Evergreen Fund

The NJEDA Board recently approved three Qualified Venture Firms (QVFs) to onboard to the New Jersey Innovation Evergreen Fund (NJIEF) platform. The QVFs will be able to apply and access up to \$12.5 million annually from the NJIEF to co-invest in innovative, high growth New Jersey-based businesses. The NJIEF is a first-of-itskind tool to increase New Jersey startups' access to venture capital and strategic resources.

CSIT to Open Applications June 5 for The \$1.5 million Round 2 of CSIT's <u>Catalyst R&D Seed Grant Program</u> - provides grants of up to \$150,000 to New Jersey startups that are developing life sciences therapeutics. Complete eligibility requirements can be found <u>here</u>. The application will be available <u>here</u> until July 14, 2023.

Upcoming Events for NJ's Life Science Community

June 13 - NJBIO 2023 HR Conference at Kean University.

June 14 – Gattefosse Lunch & Learn at NJBC. NJBC residents only

June 19-21 - SBIR/STTR National Conference—Washington DC

The <u>National Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Innova-</u> <u>tion Summit</u> will offer an opportunity to meet one on one with program managers to discuss your innovation interests and potential fit with agencies.

June 22 – <u>New Jersey Research Cores Partnering Conference</u> – Princeton University will host this event to highlight many of the core labs in the State of New Jersey that help foster collaborations and spark innovations

July (Date TBD) - Biotech Partnering Lunch & Learn at NJBC - company leaders of the Incubator only

September 28 – "Introducing The Next Generation Of NJ Life Science Companies" – NJBC to deliver this



event in partnership with Princeton BioLabs— registration tba





NEW JERSEY BIOSCIENCE CENTER

675 US-1, North Brunswick

Township, NJ 08902